NYMC Faculty Publications
The CYP/20-HETE/GPR75 Axis in Hypertension
Author Type(s)
Faculty
DOI
10.1016/bs.apha.2022.02.003
Journal Title
Advances in Pharmacology
First Page
1
Last Page
25
Document Type
Article
Publication Date
1-1-2022
Department
Pharmacology
Abstract
20-Hydroxyeicosatetraenoic acid (20-HETE) is a bioactive lipid generated from the ω-hydroxylation of arachidonic acid (AA) by enzymes of the cytochrome P450 (CYP) family, primarily the CYP4A and CYP4F subfamilies. 20-HETE is most notably identified as a modulator of vascular tone, regulator of renal function, and a contributor to the onset and development of hypertension and cardiovascular disease. 20-HETE-mediated signaling promotes hypertension by sensitizing the vasculature to constrictor stimuli, inducing endothelial dysfunction, and potentiating vascular inflammation. These bioactions are driven by the activation of the G-protein coupled receptor 75 (GPR75), a 20-HETE receptor (20HR). Given the capacity of 20-HETE signaling to drive pro-hypertensive mechanisms, the CYP/20-HETE/GPR75 axis has the potential to be a significant therapeutic target for the treatment of hypertension and cardiovascular diseases associated with increases in blood pressure. In this chapter, we review 20-HETE-mediated cellular mechanisms that promote hypertension, highlight important data in humans such as genetic variants in the CYP genes that potentiate 20-HETE production and describe recent findings in humans with 20HR/GPR75 mutations. Special emphasis is given to the 20HR and respective receptor blockers that have the potential to pave a path to translational and clinical studies for the treatment of 20-HETE-driven hypertension, and obesity/metabolic syndrome.
Recommended Citation
Froogh, G., Garcia, V., & Laniado Schwartzman, M. (2022). The CYP/20-HETE/GPR75 Axis in Hypertension. Advances in Pharmacology, 94, 1-25. https://doi.org/10.1016/bs.apha.2022.02.003